These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2006-006743-31||A Phase III Safety and Efficacy Study to Compare Immune Responses following Injection with Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®||2008-07-11||due-trials|
|Completed, but no date, and reported results||2009-015877-11||An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) among Adults (18 to 75 Years of Age) with Chronic Kidney Disease (CKD)||bad-data|
|Completed, but no date, and reported results||2010-019633-10||An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Engerix-B® and Fendrix® in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vaccina...||bad-data|
|Completed, but no date, and reported results||2010-022372-31||An Observational Study Evaluating the Long-Term Safety and Immunogenicity of HEPLISAV™ Compared with Engerix-B® in Adults With Chronic Kidney Disease Who Have Previously Received a Hepatitis B Vaccine...||bad-data|
|Exempt, with results||2016-004461-47||A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head...||2020-04-24||not-yet-due|